Pacira spent $50 million buying back 2.2 million shares at $22.28 each while posting only $2.9 million in GAAP net income — a capital allocation choice that signals management believes the stock is meaningfully undervalued, not that the business is generating the cash surplus that buyback scale implies. That tension is the real story inside an otherwise tidy quarter: 5% revenue growth to $177.4 million looks respectable, but GAAP earnings actually fell year-over-year from $4.8 million to $2.9 million as SG&A ballooned 8% to $93.9 million and R&D climbed 11% to $28.1 million. The company is spending ahead of itself on purpose, which is a defensible posture only if the pipeline delivers.
The commercial numbers carry genuine quality beneath the headline. ZILRETTA grew 15% to $26.8 million and iovera° jumped 21% to $6.2 million — both outpacing EXPAREL’s 7% volume gain, which itself was partly masked by a GPO pricing concession and storm-related returns in January. That revenue mix shift matters strategically: EXPAREL at $143.3 million still dominates, but Pacira is no longer a one-product story with accessories. The real-world evidence campaign — five studies presented at major orthopedic meetings in a single quarter — is a deliberate payer-access play, not academic exercise. Lower total cost-of-care data presented to managed care pharmacists directly targets the formulary gatekeepers who control EXPAREL’s margin profile.
The pipeline is where Pacira is making its largest bet. Enrollment is complete in the ZILRETTA shoulder OA Phase 3 registrational study, with topline data expected before year-end. A successful readout would give ZILRETTA the first on-label indication for shoulder OA pain — a clean regulatory differentiator in a crowded intra-articular space. Layered on top, Part A readout from the PCRX-201 knee OA Phase 2 and iovera° spasticity registrational data are both expected in 2026. Three binary readouts in roughly eight months is an unusual concentration of clinical risk for a company carrying $93.9 million in quarterly SG&A against a $2.9 million GAAP bottom line.
The single number to watch when ZILRETTA shoulder data land is not statistical significance — it’s the NRS pain reduction magnitude versus the knee indication, because payer willingness to reimburse a second ZILRETTA label at current ASP hinges entirely on whether shoulder OA patients show comparable effect size to justify equivalent pricing without a new-indication discount fight.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
